ad image

Company Info

Johnson & Johnson

Johnson & Johnson

Drug Discovery & Development

Overview

t Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.
Johnson & Johnson
Contributions
15 Contributions1 / 1
Johnson & Johnson
Pediatric

Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for TREMFYA®

Johnson & Johnson

PR-12-24-NI-126Dec 03, 2024
Johnson & Johnson
Large Molecule

Johnson & Johnson Submits Applications Seeking Approval as Subcutaneous Monotherapy for High-Risk moldering Multiple Myeloma

Johnson & Johnson

PR-10-24-NI-88Nov 08, 2024
Johnson & Johnson
Clinical Trials

TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with regimen in both induction and maintenance

Johnson & Johnson

PR-10-24-NI-64Oct 28, 2024
Johnson & Johnson
Clinical Trail

TALVEY and DARZALEX FASPRO shows deep and durable responses in patients with relapsed or refractory multiple myeloma

Johnson & Johnson

PR-09-24-NI-21Sep 27, 2024
Johnson & Johnson
Clinical Trails

TALVEY and TECVAYLI suggests high response rates in triple-class refractory patients with relapsed or refractory multiple myeloma

Johnson & Johnson

PR-09-24-NI-20Sep 27, 2024
Johnson & Johnson
COVID-19 Trials

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate

Johnson & Johnson

PR-M09-20-27Sep 24, 2020
Johnson & Johnson
Vaccine

European Commission Concludes Further Talks to Secure J&J COVID-19 Vaccine

Johnson & Johnson

PR-M08-20-NI-24Aug 14, 2020
Johnson & Johnson
HIV Prevention

Johnson & Johnson and Its Partners Mark a Milestone in the Quest for a Global Preventive HIV Vaccine with the Imbokodo Study

Johnson & Johnson

PR-M07-20-NI-026Jul 16, 2020
Johnson & Johnson
Vaccine

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19

Johnson & Johnson

PR-M03-20-NI-045Mar 31, 2020
Johnson & Johnson
Coronavirus

J&J Cites Lack of Evidence for HIV Treatment Against COVID-19

Johnson & Johnson

PR-M03-20-NI-026Mar 17, 2020
Johnson & Johnson
Collaboration

Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine

Johnson & Johnson

PR-M02-20-NI-017Feb 14, 2020
Johnson & Johnson
HIV

Long-Acting Injectable HIV Treatment Regimen of Rilpivirine and Cabotegravir Demonstrated Comparable Safety and Efficacy to Daily Oral HIV Therapy

Johnson & Johnson

PR-M03-19-NI-033Mar 12, 2019
Johnson & Johnson
Acquisition

Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.

Johnson & Johnson

PR-M02-19-NI-036Feb 15, 2019
Johnson & Johnson
Financial Results

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019

Johnson & Johnson

PR-M01-19-NI-010Jan 08, 2019
Johnson & Johnson
Acquistion

Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.

Johnson & Johnson

PR-M03-18-NI-071Mar 20, 2018
1 / 1
0 Contributors1 / 0

No authors found

1 / 0